Patents by Inventor Adrian Krainer

Adrian Krainer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY
    Publication number: 20230302036
    Abstract: The present disclosure relates compositions and methods to treat neuromuscular diseases and disorders, e.g., spinal muscular atrophy (SMA), characterized by the presence of a splicing silencer located in SMN2 intron 7 pre-mRNA, comprising coadministering a therapeutically effective amount of an antisense oligonucleotide (ASO) complementary to a nucleotide sequence within intron 7 of human SMN2 pre-mRNA; and a subclinical dose of a histone deacetylate inhibitor, e.g., valproic acid, trichostatin A, or a combination thereof.
    Type: Application
    Filed: July 13, 2021
    Publication date: September 28, 2023
    Inventors: Luciano E. MARASCO, Alberto R. KORNBLIHTT, Adrian KRAINER, Jose STIGLIANO
  • Reducing nonsense-mediated MRNA decay
    Patent number: 11352624
    Abstract: The present disclosure relates to compositions and methods for inhibiting nonsense-mediated mRNA decay in a gene-specific manner, for example in the treatment of diseases or disorders caused by nonsense mutations.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: June 7, 2022
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Adrian Krainer, Isabel Aznarez, Tomoki Nomakuchi
  • ANTISENSE OLIGOMERS AND USES THEREOF
    Publication number: 20220118000
    Abstract: Provided herein are methods and compositions for increasing the expression of a protein, and for treating a subject in need thereof, e.g., a subject with deficient protein expression or a subject having a disease described herein.
    Type: Application
    Filed: July 19, 2021
    Publication date: April 21, 2022
    Inventors: Isabel Aznarez, Huw M. Nash, Adrian Krainer
  • ANTISENSE OLIGOMERS FOR TREATMENT OF AUTOSOMAL DOMINANT MENTAL RETARDATION-5 AND DRAVET SYNDROME
    Publication number: 20220088058
    Abstract: Provided herein are methods and compositions for treating a subject in need thereof, such as a subject with deficient SYNGAP1 protein or SCN1A protein expression or a subject having AD mental retardation 5 or Dravet syndrome.
    Type: Application
    Filed: June 23, 2021
    Publication date: March 24, 2022
    Inventors: Isabel Aznarez, Huw M. Nash, Adrian Krainer
  • Antisense oligomers and uses thereof
    Patent number: 11096956
    Abstract: Provided herein are methods and compositions for increasing the expression of a protein, and for treating a subject in need thereof, e.g., a subject with deficient protein expression or a subject having a disease described herein.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: August 24, 2021
    Assignees: STOKE THERAPEUTICS, INC., COLD SPRING HARBOR LABORATORY
    Inventors: Isabel Aznarez, Huw M. Nash, Adrian Krainer
  • Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
    Patent number: 11083745
    Abstract: Provided herein are methods and compositions for treating a subject in need thereof, such as a subject with deficient SYNGAP1 protein or SCN1A protein expression or a subject having AD mental retardation 5 or Dravet syndrome.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: August 10, 2021
    Assignees: COLD SPRING HARBOR LABORATORY, STOKE THERAPEUTICS, INC.
    Inventors: Isabel Aznarez, Huw M. Nash, Adrian Krainer
  • TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT
    Publication number: 20210108208
    Abstract: Provided herein are methods and compositions for increasing production of a target protein or functional RNA by a cell.
    Type: Application
    Filed: May 19, 2020
    Publication date: April 15, 2021
    Inventors: Adrian Krainer, Isabel Aznarez
  • REDUCING NONSENSE-MEDIATED MRNA DECAY
    Publication number: 20200283762
    Abstract: The present disclosure relates to compositions and methods for inhibiting nonsense-mediated mRNA decay in a gene-specific manner, for example in the treatment of diseases or disorders caused by nonsense mutations.
    Type: Application
    Filed: April 2, 2020
    Publication date: September 10, 2020
    Applicant: Cold Spring Harbor Laboratory
    Inventors: Adrian Krainer, Isabel Aznarez, Tomoki Nomakuchi
  • Targeted augmentation of nuclear gene output
    Patent number: 10696969
    Abstract: Provided herein are methods and compositions for increasing production of a target protein or functional RNA by a cell.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: June 30, 2020
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Adrian Krainer, Isabel Aznarez
  • Reducing nonsense-mediated mRNA decay
    Patent number: 10647983
    Abstract: The present disclosure relates to compositions and methods for inhibiting nonsense-mediated mRNA decay in a gene-specific manner, for example in the treatment of diseases or disorders caused by nonsense mutations.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: May 12, 2020
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Adrian Krainer, Isabel Aznarez, Tomoki Nomakuchi
  • TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT
    Publication number: 20180362987
    Abstract: Provided herein are methods and compositions for increasing production of a target protein or functional RNA by a cell.
    Type: Application
    Filed: April 10, 2018
    Publication date: December 20, 2018
    Inventors: Adrian Krainer, Isabel Aznarez
  • Targeted augmentation of nuclear gene output
    Patent number: 9976143
    Abstract: Provided herein are methods and compositions for increasing production of a target protein or functional RNA by a cell.
    Type: Grant
    Filed: October 3, 2015
    Date of Patent: May 22, 2018
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Adrian Krainer, Isabel Aznarez
  • REDUCING NONSENSE-MEDIATED MRNA DECAY
    Publication number: 20170159049
    Abstract: The present disclosure relates to compositions and methods for inhibiting nonsense-mediated mRNA decay in a gene-specific manner, for example in the treatment of diseases or disorders caused by nonsense mutations.
    Type: Application
    Filed: September 4, 2014
    Publication date: June 8, 2017
    Applicant: Cold Spring Harbor Laboratory
    Inventors: Adrian Krainer, Isabel Aznarez, Tomoki Nomakuchi
  • TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT
    Publication number: 20160298121
    Abstract: Provided herein are methods and compositions for increasing production of a target protein or functional RNA by a cell.
    Type: Application
    Filed: October 3, 2015
    Publication date: October 13, 2016
    Inventors: Adrian Krainer, Isabel Aznarez
  • REDUCING NONSENSE-MEDIATED MRNA DECAY
    Publication number: 20160194630
    Abstract: The present disclosure relates to compositions and methods for inhibiting nonsense-mediated mRNA decay in a gene-specific manner, for example in the treatment of diseases or disorders caused by nonsense mutations.
    Type: Application
    Filed: September 4, 2014
    Publication date: July 7, 2016
    Applicant: Cold Spring Harbor Laboratory
    Inventors: Adrian Krainer, Isabel Aznarez, Tomoki Nomakuchi
  • PHENOCOPY MODEL OF DISEASE
    Publication number: 20140298496
    Abstract: Methods and compositions for generating nonhuman disease models through splicing modulation.
    Type: Application
    Filed: June 22, 2012
    Publication date: October 2, 2014
    Applicant: Cold Spring Harbor Laboratory
    Inventors: Adrian Krainer, Kentaro Sahashi
  • Chimeric molecules to modulate gene expression
    Publication number: 20050054836
    Abstract: The present invention provides a chimeric molecule including a base-pairing segment that binds specifically to a single-stranded nucleic acid molecule; and a moiety that modulates splicing or translation. The invention also provides a chimeric molecule including a base-pairing segment that binds specifically to a double-stranded nucleic acid molecule; and a peptide that modulates transcription, wherein the peptide comprises up to about one hundred amino acid residues.
    Type: Application
    Filed: November 9, 2001
    Publication date: March 10, 2005
    Inventors: Adrian Krainer, Luca Cartegni